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Objective: To compare cefotaxime (CTX) to amoxicillin (AMO) (usually considered the definitive therapy for penicillin- 
susceptible Streptococcus pneurnoniae infections) in an immunocompromised mouse pneumonia model. 
Methods: Three S. pneurnoniae clinical isolates were used: two serotype 19 strains, a penicillin-susceptible (Ps) strain 
(penicillin MIC = 0.03 pg/mL) and a highly penicillin-resistant (P‘) strain (penicillin MIC = 4 pg/mL), and one serotype 23F 
strain, a penicillin-cephalosporin-resistant (CFTR) strain (CTX MIC = 4 pg/rnL). 
Results: CTX activity in this mouse model of pneumonia induced by the highly penicillin-resistant strain of 
S. pneurnoniaewas lower than expected from its low MIC against this organism. Furthermore, A M 0  had greater efficacy 
than CTX against a CFTR S. pneurnoniae strain. 
Conclusion: Our data suggest that there is no major difference in the in vivo efficacy of the two agents, cefotaxime and 
amoxicillin, against penicillin-resistant and penicillin-cephalosporin-resistant S. pneurnoniae. 
Key words: Penicillin-resistant Streptococcuspneurnoniae, penicillin-cephalosporin-resistant Streptococcus pneurnoniae, 
cefotaxime, mouse pneumonia model 
INTRODUCTION 
Streptococcus pneumoniae remains the most frequently 
isolated organism in community-acquired pneumonia 
[I-31. Pneumococci retained a uniformly high degree 
of susceptibility to penicillin (MICs 0.005- 
0.01 pg/mL) throughout the first 20-25 years of the 
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antibiotic era. However, in recent years pneumococcal 
strains with various degrees of resistance have been 
reported and their frequency has increased in virtually 
every part of the world [4]. In some countries, the 
incidence of penicillin-resistant bacteria isolated from 
clinical specimens has risen to extremely high levels 
(50-70% in Spain and Hungary) [4-61. 
Broad-spectrum cephalosporins such as cefotaxime 
(CTX) have shown relatively good in vitro activity 
against penicillin-resistant strains, despite combined 
high-level penicillin resistance and higher cephalo- 
sporin MICs [7-101. For penicillin-resistant isolates, 
the MICs of CTX have generally been two to eight 
times lower than the respective MICs of penicillin 
[8,11,12]. Thus, these increased MICs have remained 
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far below serum levels of CTX [13,14]. This better 
in vitro activity of CTX has suggested that it might 
be useful in the treatment of penicillin-resistant (p? 
S. pneumoniae infection. For this reason, in areas of the 
world with high incidence of P' pneumococci, third- 
generation cepbalosporins (e.g. CTX) have been 
considered the chemotherapeutic agents of choice for 
empirical therapy of severe community-acquired 
pneumonia [2,15,16]. Notably, the American Thoracic 
Society has recommended use of a third-generation 
cephalosporin in this setting [17]. 
However, more recently, penicillin-cephalosporin- 
resistant (CFTR) S. pneumoniae strains have been 
described for which CTX MICs were unusually higher 
than the penicillin MICs [11,18-211. Because of the 
emergence of CFTR S. pneumoniae strains, the optimal 
antibiotic therapy for initial empirical management of 
severe community-acquired pneumonia is not clear. 
CFTR pneumococci have been associated with failed 
CTX therapy for meningitis [19,21], and third- 
generation cephalosporins would seem to offer little 
advantage over high-dose penicillin or amoxicillin for 
the treatment of pneumonia or septicemia due to such 
strains. 
We therefore compared the efficacy of CTX with 
that of amoxicillin (AMO), usually referred to as the 
definitive therapy for penicillin-susceptible (P') S. 
pneurnoniae infections [22], in a mouse model of acute 
pneumonia induced by P', P' and CFTR S. pneumoniae 
strains. 
MATERIALS AND METHODS 
Animals 
Female Swiss mice (aged 6-8 weeks, body weight, 
20-24 g) were obtained from Iffa-Credo Laboratories, 
France. 
Challenge organisms 
We failed to induce pneumonia with any P' strain in 
immunocompetent mice. All of these strains belonged 
to serotypes 6, 9, 14, 19 and 23, which are naturally 
avirulent for mice independently of their isolation sites 
in humans [23,24]. Thus. pneumonia was induced in 
leukopenic Swiss mice. Three S. pneumoniae clinical 
isolates with different levels of susceptibility to A M 0  
and CTX were used in this study: two serotype 19 
strains, a P' strain originally isolated from blood culture 
(strain P52181, provided by Hapita1 Xavier Bichat- 
Claude Bernard, Paris, France) and a highly P' strain 
(penicillin MIC = 4 pg/mL) originally isolated &om 
middle ear fluid (strain P15986, provided by the Centre 
de Rtftrence du Pneumocoque (P. Geslin), Crtteil, 
France), and one serotype 23F strain, a CFTR strain 
(cefotaxime MIC = 4 pg/mL) originally isolated from 
middle ear fluid (strain P40422, provided by the Centre 
de Rtftrence du Pneumocoque (l? Geslin), Crtteil, 
France). 
Antibiotics 
The drugs used in this study were CTX (Roussel-Uclaf 
Laboratories, Paris, France) and A M 0  sodium salt 
(Beecham Laboratories, Paris, France). The antibiotics 
were reconstituted according to the instructions on the 
package insert and diluted in sterile water to the desired 
concentrations. 
In vitro studies 
MICs and minimum bactericidal concentrations 
(MBCs) were determined for each strain in Mueller- 
Hinton infusion broth supplemented with 5% lysed 
horse blood (Bio-Mtrieux, Lyon, France) by means of 
the tube-dilution method [25]. Each tube contained 
twofold dilutions of antibiotic and a final bacterial 
density of lo6 CFU/mL. After aerobic incubation for 
18 h at 37"C, the MIC was defined as the lowest con- 
centration of antibiotic at which no turbidity was 
visible to the naked eye. The MBC was determined by 
plating 0.01-mL aliquots froin tubes with no visible 
growth onto Columbia agar supplemented with 5% 
sheep blood (Bio-Mtrieux, Lyon, France). The plates 
were incubated overnight at 37OC, and the MBC was 
defined as the lowest concentration of antibiotic kdling 
2 99.9% of the original inoculum. 
leukocyte depletion in mice 
We induced sustained leukopenia in Swiss mice by daily 
intraperitoneal injections (150 mg/kg body weight) of 
cyclophosphamide (Endoxan; Sarget Laboratories, 
Mtrignac, France) starting 3 days before infection. 
Counts of circulating leukocytes per cubic millimeter 
of blood were reduced from about 7000 to 800 on the 
day of infection. Under these conditions, mice became 
more susceptible to the poorly virulent P and P' 
serotype 19 strains and the CFTR serotype 23F strain. 
Experimental pneumococcal pneumonia in mice 
Animals were infected by intratracheal instillation via 
the mouth as described in detail elsewhere [26]. Briefly, 
animals were anesthetized intraperitoneally with 
0.2 mL of 0.65% sodium pentobarbital and were 
suspended by the upper incisors. The trachea was 
cannulated via the mouth with a blunt needle, and 
50 pL of bacterial suspension (10' CFU of P', P' or 
CFTR S. pneumoniae per mouse) was instilled. 
Leukopenic mice developed acute pneumonia and died 
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within 2-3 days. AU the animals quickly became 
bacteremic. Bacterial counts exceeded 10' CFU/ 
lungs of infected mice at the time of their death 
(2 lo6 CFU/mL of blood). 
Survival studies 
Therapy was initiated 3 h after bacterial challenge. 
With P', P" and CFTR strains, Ah40 and CTX were 
administered at 12-h intervals with a total of six 
injections. The dose of each antibiotic varied with the 
infective strain. Mice infected with P52181 were 
treated with Ah40 or CTX at 5 mg/kg. Mice infected 
with P15986 were treated with AM0 at 200 or 
300 mg/kg, or with CTX at 100 or 200 mg/kg. Mice 
infected with P40422 were treated with AM0 at 100 
or 150 mg/kg, or with CTX at 200 or 300 mg/kg. 
In order to determine the influence of the schedule 
of drug administration on efficacy, AM0 and CTX 
were also administered at 6-h intervals with a total of 
12 injections. Thus, mice infected with P15986 were 
treated with AM0 at 150 mg/kg or with CTX at 
100 mg/kg. 
Detailed treatment schedules are presented in the 
figure legends, together with the results. Fifteen animals 
per treatment group were used, and in each experiment 
the animals were infected simultaneously. The observ- 
ation period was 14 days. Death rates were recorded 
daily and cumulative survival rates were compared. 
Controls received identical treatment with isotonic 
saline. 
Bactericidal activity in vivo 
The study drugs were assessed for their ability to 
eradicate bacteria from the lungs. Drug administration 
was started 3 h after infection and consisted of a single 
dose of AM0 or CTX. Various doses (5, 10, 100, 200, 
400mg/kg of body weight) of each drug were 
administered in 0.5 mL of sterile water according to the 
infective strain. Controls received the same volume of 
isotonic saline. The total CFUs recovered from whole- 
lung homogenates were determined 1, 3, 6 and 8 h 
after one injection. Mice were killed by C0z 
asphyxiation and exsanguinated by cardiac puncture 
(the blood was used for cultures). The lungs were 
removed and homogenized in 1 mL of sahne. Serial 10- 
fold ddutions of the homogenates were plated onto 
Columbia agar (0.1 mL/9-cm-diameter plate). Results 
are expressed as the mean log CFU per lung k standard 
deviation for groups of three mice. The lower limit of 
detection was 2 log CFU per lung, which corres- 
ponded to the weakest dilution of tissue homogenates 
(1 0-') that avoided significant drug carryover with 
control inocula. 
Pharmacokinetic studies 
The pharmacohnetic profiles of AM0 and CTX were 
examined in parallel in infected Swiss mice. 
Bioassay 
Concentrations in lungs and sera were determined after 
single subcutaneous doses of 200 and 300 mg/kg of 
AM0 and 200 mg/kg of CTX. In infected mice, the 
antibiotic was given 3 h after challenge with strain 
P15986. At 0.5, 1, 2, 4, 6, 8, 12 and 24 h following 
drug administration, three animals per group were 
killed with C02 and exsanguinated by cardiac punc- 
ture. Blood samples were centrifuged to isolate serum, 
pooled, and frozen at -80°C until assay. Lungs were 
harvested from exsanginated mice, washed in sterile 
sodium chloride solution, and frozen. On the day of 
assay, organs were weighed, pooled, and homogenized 
in phosphate buffer (pH = 6.8). Homogenates were 
centrifuged, and supernatants were used for assay. 
AM0 concentrations were determined by the agar 
well diffusion method using Sarcina lutea ATCC 9341 
as the bioassay organism and Antibiotic Medium 1 
(Difco Laboratories, Detroit, Michigan) as the growth 
medium. CTX concentrations were determined by the 
agar well diffusion method using Escherickia coli ATCC 
391 18 as the bioassay organism and Antibiotic Medium 
1 (Difco Laboratories, Detroit, Michigan) as the 
growth medium. Standard curves were determined 
with solutions of AM0 and CTX in phosphate buffer 
for serum and tissue in order to evaluate the active 
fractions of the drugs. Results are expressed as 
micrograms per milliliter of blood or per gram of lung 
tissue. The standard curve was linear from 0.125 to 
32 pg/mL. The sensitivity of the assay was about 
0.1 pg/mL of sample, and the coefficient of between- 
and within-day variations for replicates (n = 5) was 
~ 7 . 5 %  at 0.5, 1, 7.5, and 20 pg/mL. 
Analysis 
Pharmacokinetic analyses were performed by routine 
graphical methods, and parameters were estimated by 
standard methods [27]. C,,, is the maximal concen- 
tration observed; t a p  is the terminal-elimination half- 
life at fi phase calculated by using linear least-squares 
regression for the log linear terminal-elimination phase; 
A ~ M I c  is the time during which concentrations exceed 
the MIC for the test pathogen; and AUCo-24 is the area 
under the concentration-time curve from 0 to 24 h, 
calculated by the trapezoidal rule. 
Statistical analysis 
Survival rates were analyzed by using an unpaired t-test. 
Analysis of variance (repeated measures) was used to 
compare CFU values. P values of 0.05 or less were 
considered statistically significant. 
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RESULTS 
In-vitro data 
The properties of the three strains are shown in Table 1. 
Serum and lung pharmacokinetics 
After a single subcutaneous injection of 200 mg/kg, 
CTX showed a lower peak concentration in serum and 
a smaller AUC than A M 0  (Table 2). The elimination 
half-life in serum was shorter for CTX than for A M 0  
(0.35 versus 0.41 h). Similarly, compared to CTX, 
A M 0  showed higher peak levels in the lung (22 versus 
13 pg/mL), a longer pulmonary half-life (1.4 versus 
0.33 h), and a larger AUC (31 versus 10 pg h/mL). 
Bacterial clearance from lungs 
Results with the P strain are presented in Table 3. 
Three hours after a single-dose injection (AM0 a t  
5 mg/kg; CTX at 5 and 10mg/kg), the intrapul- 
monary bacterial decrease was significant for both 
compounds relative to the control value ( P  < 0.05). 
CTX was the most rapidly bactericidal agent. 
Results with the P' strain were as follows (Table 4). 
Three hours after a single subcutaneous injection of 
Table 1 Microbiological data for S. pneumoniae challenge 
strains and study d r u s  
MIC/MHC (pg/mL) 
P 52181 P 15986 P40422 
Study drug ( "$1 (P9 (CFTR) 
Penicillin 0.03/0.03 4/8 214 
Amoxicilliri 0.03/0.03 2/4 214 
Cefotaxime 0.03/0.03 0.5/1 4/8 
I", petiicillin-susceptible strain; 
P', penicillin-resistatit strain; 
CFTR, penicillin-cephalosporin-resistant strain 
CTX (100 and 200 mg/kg) or AM0 (200 and 
300 mg/kg), bacterial counts in the lungs were signific- 
antly lower than in controls ( P  < 0.01). However, with 
CTX (200mg/kg) a longer antibacterial effect was 
observed compared with that of AM0, as shown by a 
1.6-log-unit reduction in CFU, 8 h after a single 
administration. In contrast, pulmonary bacterial counts 
in the 200 mg/kg AMO-treated group remained 
unchanged over the 8 h following a single adminis- 
tration. Nevertheless, AM0 at 300 mg/kg exhibited a 
0.9-log-unit reduction in CFU, 8 h after a single 
administration. 
Results with the CFTR strain are presented in 
Table 5. Four hours after a single administration of 
AM0 (200mg/kg) or CTX (200 and 400mg/kg), 
bacterial counts in the lungs were not significantly lower 
than in controls. However, with AM0 (200 mg/kg) a 
significant antibacterial effect was observed compared 
with that of CTX, as shown by a 1.2-log-unit 
reduction in CFU, 8 h after a single administration. 
Therapeutic efficacy in experimental pneumonia 
With P strain P52181 (treatment initiated 3 h after 
infection and consisting of six subcutaneous injections 
at 12 h intervals over 72 h), both A M 0  and CTX at 
5 mg/kg were associated with an 85% survival rate 
( P  < 0.001 versus untreated control group (0%)). A 
100% survival rate was achieved with CTX at 
25 mg/kg (data not shown). 
Results with the P' strain were as follows. A 40- 
fold-higher dose of CTX (200 mg/kg) gave protection 
(75% survivors) similar to that obtained against the P' 
strain ( P  = 0.3), whereas a 60-fold higher dose ofAh4O 
was required (300 mg/kg) to confer equal protection 
(Figure 1). The survival rate was not significantly 
improved with larger doses of either drug. 
In order to determine the influence of the schedule 
of drug administration on efficacy, the same daily 
Table 2 
dose of 200 and 300 mg/kg of amoxicillin, and 200 mg/kg of cefotaxime! 
Pharmacokmetic parameters of amoxiciuin and cefotaxime in infected Swiss mice following a single subcutaneous 
C,,,.lxb AUC 0-24 
(pg/niL or AtM1c:C (pg h/mL or AUC/MIC Dose/MIC: 
Drug Site t1/2R (h) (4 Pg h/g) ratio' ratio' 
AmoxiciKiii 200 mg/kg Serum 118k 12 0.41 3.3 92 46 100 
Ainoxicillin 300 mg/kg Serum 156 * 21 0.43 3.5 13.5 67 1 50 
Cefotaxime 200 mg/kg Serum 101 ? 10 0.35 3.8 80 160 400 
Lung 22 * 6 1.4 3.7 31 ~ - 
Lung 36 k 9 1.3 4.2 46 ~ - 
Lung 13 f 6 0.40 2.1 10 ~ - 
Values are calculated from mean Concentrations in serum and in lung tissue sample5 taken at 0.5, 1, 2, 4, 6, 8 and 24 h post-dosing. A M 0  
C,,,,,, maximum concentration ohserved. Values are means I standard deviation from groups of three mice. 
and CTX concentrations were determined by the agar well diffusion method. 
' Value5 calculated for the P'strain (P15986; MICs 2 for A M 0  and 0.5 for CTX). 
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Table 3 
subcultaneous injection of study drugs 
Clearance of S. pneumoniae from lungs and blood of Swiss mice infected with Ps strain P52181 following a single 
Values after treatment with 
Control Amoxicillin (5 mg/kg) Cefotaxime (5 mg/kg) Cefotaxime (10 ing/kg) 
Time ~ 
(h) Lung" Blood' Lung Blood Lung Blood Lung Blood 
1 5.33 f 0.35 313 4.58 ? 0.51 3/3 4.14k 1.17 3/3 3.77 f 0.1lC 313 
3 5.74 k 1.04 3 / 3  3.97 f 0.45' 3/3 3.03 f 0.63' 313 2.78 ? 0.69' 2/3 
6 3.69 f 0.81 0/3 2.54 f 0.81 0/3 1.87 ? 0.23 0/3 
8 5.96 f 0.97 313 4.26 f 0.24 0 /3  1.43 ? 0.51' 0/3 1.33 f 0.58' 0/3 
- __ 
~ ~ ~ 
Loglo CFU per niilliliter of lung homogendte Values are means ? standard deviations ( n  = 3) 
Value lower than for the control group ( P  1 0  05) 
" Number of animals with pocitive blood cultures/total nuniber of animals 
Table 4 
subcutaneous injection of study drug 
Clearance of S. pneurnoniae from lungs and blood of Swiss mice infected with P' strain P15986 following a single 
Values after treatment with 
-~ 
Anioxicillin Amoxidin C efo taxime Cefotaxime 
Control (200 mg/kg) (300 mg/kg) (100 mg/kg) (200 mg/kg) 
Time (h) Lung' Blood' Lung' Blood' Lunga Bloodh Lung" Blood' Lung" Blood' 
6.55 f 0.17 3 / 3  1 7.10 f 0.22 1/3 6.94 k 0.39 3/3 6.76 ?c 0.40 3/3 6.80 f 0.03 313 
3 7.63 f 0.06 1/3 6.20 f 0.64' 3/3 6.12 ? 0.38' 3/3 6.33 ? 0.25' 3/3 6.36 f 0.27' 3 / 3  
6 ~ 6.52 ? 0.19 3/3 5.48 f 0.4jd 3/3 6.10 f 0.40 3/3 5.44 f 0.47" 2/3 
8 7.42 f 0.40 3/3 6.96 +- 0.38 2/3 5.86 f 0.32c-d 2/3 6.0 O f  0.51'." 2/3 4.99 ? 0.04',d,' 213 
- 
Log," CFU per milliliter of lung homogenate. Values are ineans f standard deviations ( n  = 3). 
Value lower than for the control group ( P  c0.01). 
Lower than value for A M 0  at 200 mg/kg ( P  <0.03). 
Lower than value for A M 0  at 300 mg/kg ( P  10.03). 
' Number of animals with positive blood culturedtotal number of animals. 
Table 5 
single subcultaneous injection of study drugs 
Clearance of S. ptzecrrnoniae from lungs and blood of Swiss mice infected with CFTR strain P40422 following a 
Values after treatment with 
Control Amoxicillin (200 nig/kg) Cefotaxime (100 mg/kg) Cefotaxime (200 mg/kg) 
~ Time ~- ._________- ~ 
(h) Lung" Blood' Lung Blood Lung Blood Lung Blood 
1 7.48 i 0.14 3/3  7.20 ? 0.25 0/3 7.10 i 0.06 213 7.03 ? 0.24 1 / 3  
4 7.10 i 0.35 3/3  7.01 ? 0.62 0/3 7.21 i 0.29 1/3 6.69 i- 0.25 0/3 
8 7.37 i 0.23 3/3 h.24? 0.18' 0/3  7.03 ? 0.11 1/3 6.69 f 0.26 0/3 
Loglo CFU per milliliter of lung homogenate. Values are ineans ? standard deviations (n = 3). ' Number of animals with positive blood culturcs/total nuniber of aniinals. 
' Value lower than for the control group ( P  <0.05). 
amounts of A M 0  (600mg/kg per day) and CTX (AM0 300mg/kg and CTX200 mg/kg) at 12-h 
(400 mg/kg per day) were administered more intervals (Figure 2). Moreover, the 12-injection 
frequently. With the P' strain, we did not find greater regimen gave 60% survival with CTX 100 mg/kg, 
efficacy with 12 subcutaneous injections (AM0 150 versus 45% with AM0 150 mg/kg. 
mg/kg and CTX 100 mg/kg) at 6-h intervals over 72 h With the CFTR strain (treatment initiated 3 h 
compared with that of six subcutantous injections after infection and consisting of six subcutaneous 
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--t cefotaxime 200 mgkg 




-0- amoxicillin 200 mg.kg 
cefotaxime 100 mgkg 
Control 
0 2 4 6 8 1 0 1 2 1 4  
Days postinfection 
Figure 1 
leukopenic Swiss mice after intratracheal challenge 
with 10’ CFU of the highly P’ S. pneuwoniae strain 
P15986. From 3 h postinfection (pi), mice received six 
subcutaneous administrations of the amounts of drug 
at 12-h intervals. 
Cumulative survival of treated and control 
Percent survivors 
100 
---)--. cefotaxime 200 mgkg 12-hi 




* amoxicilli 150 mgkg 6-hi 
Control -
Treatment initiation: 3 h pi 
0 I I I I 1 I I 
0 2 4 6 8 1 0 1 2 1 4  
Days postinfection 
Figure 2 
on efficacy. Cumulative survival of treated and control 
leukopenic Swiss mice after intratracheal challenge of 10’ 
CFU of the highly P‘ S. pneumoniue strain P15986. From 
3 h postinfection (pi), mice received six or 12 subcutaneous 
administrations of the indicated amounts of the drug at 
12-h (12-hi) or 6-h (6-hi) intervals respectively. 
Influence of the schedule of drug administration 
Percent survivors 
-C- amoxicillin 150 mgkg 
-+-- cefotaxime 300 mgkg 
+ amoxicilli 100 mgkg 
----C cefotaxime 200 mgkg 
40 
Control  20 
reatment initiation: 3 h pi 
0 
0 2 4 6 8 1 0 1 2 1 4  
Days postinfection 
Figure 3 
leukopenic Swiss mice after intratracheal challenge with 
10’ CFU of the CFTR S. pneurnoniae strain P40422. From 
3 h postinfection (pi), mice received six subcutaneous 
administrations of the inchcated amounts of the drug at 
12-h intervals. 
Cumulative survival of treated and control 
injections at 12-h intervals over 72 h), a 30-fold higher 
dose of A M 0  (150mg/kg) gave protection (77% 
survivors) similar to that obtained against the P strain, 
whereas a 60-fold higher dose of CTX was required 
(300 mg/kg) to confer equal protection (Figure 3). 
DISCUSSION 
The data obtained with this mouse model of pneu- 
monia showed that CTX and AM0 were effective 
against a highly P’ S. pneumoniue strain. At a dose of 
200 mg/kg, CTX showed marked bactericidal activity, 
whereas 300 mg/kg of AM0 was required to achieve 
the same therapeutic efficacy. Nevertheless, the CTX 
MIC for the P’ strain was fourfold lower than that 
of AMO. The pharmacokinetic properties of CTX 
and AM0 in serum were probably a factor in the 
relative efficacy of the two agents against highly P‘ 
pneumococci in vivo, alongside their MICs for this 
organism. CTX exhibited shorter half-lives than AM0 
in serum and lungs, and smaller AUCs. Since both 
drugs undergo 20-30% protein binding in mouse 
serum, protein binding &d not explain the difference. 
In general, it appears that the therapeutic activity of 
fi-lactams is mainly determined by maintenance of 
antibiotic concentrations in serum above the MIC 
during treatment [28,29]. In this model with a highly 
6 1 4  Cl in ica l  M i c r o b i o l o g y  and In fec t ion ,  Vo lume 3 Number  6, December 1997 
P' S. pneumoniae strain (penicillin MIC = 4 pg/mL), the 
time during which CTX serum levels exceed the MIC 
(AtM,c) was not the parameter most predictive of 
efficacy, as the A M 0  and CTX AtMIcs  were similar 
(3.5 versus 3.8 h, respectively). Moreover, measured 
AUC/MIC ratios were predictive of bacterial eradic- 
ation, and CTX had a higher AUC/MIC ratio than 
AM0 (160 versus 67). In lung bactericidal activity, 
CTX was indeed more effective than AMO, as shown 
by a 2.0-log-unit reduction in CFU versus a 1.2-log- 
unit reduction in CFU, 8 h after a single administration. 
However, in this model with a highly P' S. pneumoniae 
strain, CTX appeared to have lower antimicrobial 
potency, as confirmed by its higher dose/MIC ratio 
(CTX 400 versus AM0 150). 
Using the same mouse model of pneumonia, we 
previously found that ceftriaxone (CRO) had greater 
efficacy than AM0 against a hlghly P' S. pneumoniae 
strain (strain P15986; penicillin MIC = 4 pg/mL) [30]. 
At a dose of 50mg/kg, CRO showed sustained 
bactericidal activity with serum and tissue concentra- 
tions that remained far hlgher than the MIC for the 
challenge strain (CRO MIC, 0.5 pg/mL). The AtMIc  
appeared to be the main pharmacodynamic parameter 
correlating with CRO efficacy in this model. At a dose 
of 50 mg/kg, measured CRO AUCIMIC and dose/ 
MIC ratios were 193 and 100, respectively. 
The schedule of drug administration may have an 
important influence on efficacy, particularly in this 
neutropenic model [29,31]. One would expect that 
with drug-organism combinations-e.g. f3-lactam Ps 
S. pneumoniae--for which the time above the MIC is 
the important parameter, more kequent dosing would 
be more effective. Moreover, it has been suggested that 
p-lactam regimens should be selected to maximize the 
time for which drug levels exceed the MIC and that 
drugs should be given at intervals no greater than the 
time above the MIC plus the duration of the 
postantibiotic effect, if relevant [31, 321. In this model, 
we found no gain in efficacy with more frequent 
administration of the same daily amount of CTX or 
AM0 against S. pneumoniae. Moreover, with this P' test 
strain (P15986), our results suggested that the 
therapeutic activity of AM0 and CTX was mainly 
dependent on the total dose of antibiotic administered, 
irrespective of the frequency of administration. 
Nevertheless, our study was limited by failure to use a 
continuous infusion regimen that achieved levels above 
the MIC. 
Our data from a mouse model of pneumonia 
showed that AM0 had greater efficacy than CTX 
against a CFTR S. pneumoniae strain (cefotaxime 
MIC = 4 pg/mL). At a dose of 150 mg/kg, A M 0  
showed marked therapeutic efficacy, whereas 300 mg/kg 
of CTX was required to achieve the same efficacy. 
Nevertheless, the MIC of AM0 for the test CFTR 
strain was twofold lower than the respective value for 
CTX. Few authors have described clinical pneumo- 
coccal isolates with a high level of resistance to third- 
generation cephalosporins [11,18,21]. Moreover, 
CFTR pneumococci have been associated with failed 
CTX therapy [19,33]. These CFTR strains appeared 
unusual relative to other P' isolates with regard to 
several properties [l 11. Indeed, they had an inversion of 
the relative MICs of penicillin and A M 0  compared 
with those of expanded-spectrum cephalosporins; 
unlike P' strains, CFTR strains lysed quickly with 
penicillin; and they had patterns of penicillin-binding 
proteins (PBP) which were atypical compared with 
those of P' pneumococci [ll]. CFTR isolates had the 
same PBP electrophoretic profile as the susceptible 
strains, and there appeared to be relatively little, if any, 
affinity change in PBP 2B [ll] .  This is in contrast to 
the situation with highly P' isolates, in which PBP 2B 
could not be detected [11,34]. According to our results, 
CTX would not seem to offer any advantage over high- 
dose AM0 for the treatment of pneumonia due to such 
strains. 
In conclusion, cefotaxime activity in an im- 
munocompromised mouse model of pneumonia 
induced by a highly P' strain of S. pneumoniae 
(penicillin MIC = 4 pg/mL) was lower than expected 
from its low MIC against this organism (cefotaxime 
MIC = 0.5 pg/mL). Furthermore, AM0 was more 
effective than CTX against a CFTR S. pneumoniae 
strain (CTX MIC = 4 pg/mL). Our data suggest that 
there is no major difference in the in vivo efficacy of 
the two agents, CTX and AMO, against P' and CFTR 
S. pneumoniae strains, although this remains to be 
confirmed in clinical studies. 
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